REMARKS

Reconsideration of this application is requested.

Non-elected claims 10-14 have been retained. It is believed, for the reasons noted below, that product claim 1, as amended, is allowable. Claims 10-14 depend indirectly from claim 1. Rejoinder of claims 10-14 with allowance thereof is thought to be in order with allowance of claim 1.

Claim 1 has been amended to include the limitations of claim 6 with some broadening in the A and B definitions as follows:

A Substituents	Support
three substituents	Examples 7, 8, 17, 18, 21-24, 27, 29, 32 and 34
nitro	Examples 44 and 47; specification, page 2, 3rd ¶, line 2
optionally substituted C ₁₋₆ alkoxy	Examples 33, 37 and 46; specification, page 2, 3rd ¶ line 7
optionally substituted C ₁₋₆ alkyl	Example 26 (two structures); specification, page 2, 3rd ¶, line 6
N-oxamoyl	Example 56
B Substituents	
amino	Example 59; specification, page 3, 2nd ¶, line 2
acetamido	Example 58

Claims 3 and 7 have been canceled and claim 4 amended in view of the indicated amendment of claim 1.

In view of the amendments to claim 1, the Examiner is requested to reconsider and withdraw (a) the Section 102(b) rejection of claims 1-3 as anticipated by Andrew et al. (U.S. 3,207,746) and (b) the Section 103(a) rejection of claims 1, 3, 4, 8 and 9 as being unpatentable over Sakaeda et al. (JP 01135880). Claim 6 was not included in these rejections and, as noted, claim 1 has been amended to include the substance of claim 6 with some broadening as to the substituents called for with respect to A and B. This broadening does not impact on the acknowledged patentability of the claim 6 subject matter. Clearly, Andrew et al. and Sakaeda et al. do not disclose or suggest the invention defined by amended claim 1. Accordingly, it is submitted that claim 1, and consequently all of the applicants' other claims, define subject matter which is new and unobvious and, therefore, patentable.

The Examiner is requested to reconsider the double-patenting rejections based on U.S. 7,041,161 and Application No. 12/224,616. While the applicants do not agree with the Examiner's rejections, the attached Terminal Disclaimers should moot the issue.

All issues having been addressed, the application is thought to be in condition for allowance and such action is requested.

Respectfully submitted,

MORGAN LEWIS & BOCKIUS LLP

 $3y\sqrt{-2}$

Reg. No. 16773

Date: May 8, 2009

Customer No. 09629 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004

Phone: (202) 739-3000 Facsimile: (202) 739-3001 Direct: (202) 739-5455